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1. Introduction
Diabetes affects 25.8 million people, or 8.3% of the U.S. population. Among people with
diabetes, 26% are insulin users.[1] Therapy with insulin is effective at lowering blood glucose
in patients with diabetes. Insulin is a key player in the control of diabetes for patients with
type 1, and it is required at later stages by patients with type 2. Hyperglycemia in type 1
diabetes is a result of the deficiency of insulin, and in type 2 diabetes hyperglycemia is due to
impaired tissue response to insulin.
The discovery of insulin is hailed as one of the most dramatic events in the history of the
treatment of disease. It was isolated in 1921, with its first clinical use in 1922.[2] The major
advances achieved in this area include the human insulin analogue synthesis. Insulin delivery
systems currently available for insulin administration include syringes, infusion pumps, jet
injectors, and pens. The traditional and most predictable method for insulin administration is
by subcutaneous injections. The major drawback of current forms of insulin therapy is their
invasive nature. In type 1 diabetes, good glycemic control usually requires at least two, three,
or more daily insulin injections. To decrease the suffering, the use of supersonic injectors,
infusion pumps, sharp needles, and pens has been adopted.
Such invasive and intensive techniques have spurred the search for alternative, more pleasant
methods for administering insulin. Several non-invasive approaches for insulin delivery are
being pursued. The ultimate goal is to eliminate the need to deliver insulin exogenously and
for patients to regain the ability to produce and use their own insulin. The success of the
administration route is measured by its ability to elicit effective and predictable lowering of
blood glucose level, therefore minimizing the risk of diabetic complications. Newer methods
explored include the artificial pancreas with a closed-loop system, transdermal insulin, and
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buccal, oral, pulmonary, nasal, ocular, and rectal routes. This chapter focuses on the new
methods that are being explored for use in the future.
2. Current methods in insulin therapy
Current methods of insulin delivery include using syringes, continuous subcutaneous insulin
infusion (CSII), and insulin pens. Use of syringes is the most common method, and there is a
wide choice of products that are easy to read and operate. CSII, also referred to as an insulin
pump system, is designed to provide a continuous supply of insulin infusion around the clock
and can be individualized and adjusted as per the specific needs of the patient. CSII is a way
to simulate the physiology of daily insulin secretion where an appropriate level of insulin is
delivered. The use of an insulin pump is superior to multi-dose insulin injections because it is
easier to use and therefore provides the patient with more flexibility. A disadvantage is that
insulin pump therapy is expensive compared to the use of traditional syringes and vials.
Insulin pen devices offer an alternative method for insulin delivery that is more accurate and
less painful versus vials and syringes.[3] Reusable insulin pens offer a number of advantages
including durability and flexibility in carrying a multiple days’ supply.
3. Future trends (Table 1)
Injectable insulin: Two promising new insulin preparations include a long-acting basal
insulin analogue called insulin degludec and an ultrafast-acting insulin analogue, human
insulin Linjeta™ (formally called VIAject®).
Insulin degludec is novel, ultra-long-acting basal insulin.[4] Insulin degludec is almost
identical to human insulin in structure except for the last amino acid deleted from the B-chain
and addition of a glutamyl link from LysB29 to a hexadecandioic fatty acid.[4] It forms soluble
multi-hexamers after subcutaneous injection, resulting in an ultra-long action profile with a
half life of more than 24 hours.
Insulin degludec has proven to be non-inferior to currently available, long-acting insulin
analogue insulin glargine in trials carried out in both type 1 and type 2 diabetes.[5-6] In an
exploratory phase 2 trial in subjects with type 1 diabetes, insulin degludec was found to be
safe and well tolerated and had comparable glycemic control to insulin glargine, but with
reduced rates of hypoglycemia.[7] In a multicenter phase 3 clinical trial in adults with type 1
diabetes, at one year, compared to insulin glargine, glycemic control was similar to glycemic
control using glargine with decreased nocturnal hypoglycemia.[6] Similarly, in an open-label
phase 3 non-inferiority trial in type 2 diabetes patients, improvement in glycemic control was
comparable to insulin glargine at one year follow-up (drop in HbA1C by 1.1% in the degludec
group and 1.2% in the glargine group) with fewer hypoglycemic episodes in insulin degludec
users.[5] Insulin degludec is not yet approved by the FDA.
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Linjeta™, formally called VIAject®, is recombinant human insulin with a fast onset of action.
In a study of pharmacodynamics and pharmacokinetic properties of an ultrafast insulin, it was
found to have an earlier onset of action and shorter time to maximal plasma insulin concen‐
tration. VIAject®, compared to human insulin, had less within-subject variability of plasma
insulin.[8] In a double blind, three-way crossover study with VIAject® compared to lispro
insulin, VIAject® was found to be bioequivalent to the previously used formulation and had
a faster absorption/onset of action than insulin lispro.[9] VIAject® is currently undergoing two
pivotal phase 3 clinical studies for both type 1 and type 2 diabetes. Since the VIAject®
pharmacodynamics mimic 1st phase release insulin and the amount of insulin circulating
several hours after a meal, it leads to possible reduction in hypoglycemia, and it is predicted
to possibly prevent weight gain.[8]
Artificial pancreas: Closed-loop insulin delivery is an emerging therapeutic approach for
people with type 1 diabetes. [10] Even with the use of continuous glucose monitors and insulin
pumps, most people with type 1 diabetes do not achieve glycemic goals and continue to have
unacceptable rates of hypoglycemia. The goal of closed-loop therapy is to achieve good
glycemic control with the use of a control algorithm that directs insulin delivery according to
glucose levels while reducing the risk of hypoglycemia. Insulin delivery in the closed-loop
system is modulated at intervals of 1-15 minutes, depending on interstitial glucose levels. The
uniqueness of this approach is the real-time response of insulin delivery to the glucose levels,
similar to that of the beta-cell. The algorithms that are most relevant include the proportional-
integral-derivative control (PID) and the model-predictive control (MPC).[11]
Several areas need improvement to have a near normal closed-loop system. First and foremost
is the rapid onset of action. The lag period of current fast-acting insulin analogs is 90-120
minutes. Current trials show promise. In a phase 2 study with or without recombinant human
hyaluronidase (rHuPH20) that accelerates insulin absorption in healthy volunteers, both lispro
and recombinant human insulin with rHuPH20 produced earlier and greater peak insulin
concentrations, improved postprandial glycemic control, and reduced hypoglycemia.[12]
Rapid acting insulins are being developed that use monomeric insulins that cannot form
hexamers.[13] As mentioned earlier, ultrafast insulin VIAject®, a formulation of human
soluble insulin, improves the rate of insulin absorption. It has been reported in a study to
evaluate its pharmacodynamics and pharmacokinetic properties that VIAject® has higher
metabolic activity in the first two hours after injection.[14] True closed-loop systems, which
determine minute-to-minute insulin delivery based on continuous glucose sensor data in real
time, have shown promise in small inpatient feasibility studies using a variety of algorithmic
and hormonal approaches.
Buccal delivery of insulin: The buccal delivery system for insulin delivers insulin through an
aerosol spray into the oral cavity and hence differs from inhalers. The insulin is absorbed
through the inside of the cheeks and in the back of the mouth instead of the lungs. In vivo
studies performed on diabetic rats showed promising results with stable blood glucose profile
with a significant hypoglycemic response after 7 hours using buccal insulin.[15] Similar studies
in the rabbit and rat have shown that buccal spray of insulin is an effective insulin delivery
system, which is promising for clinical trial and future clinical application.[16] Though
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promising in rat models, they are not appropriate models because rats have a keratinized
buccal mucosa. The only animal models with comparable human buccal permeability are pigs.
Oral-lynTM: Generex Biotechnology Corporation (Toronto, Canada) is developing a buccal
insulin formulation based on RapidMistTM, an advanced buccal drug delivery technology.
[17] Oral-lynTM is a liquid formulation of human regular insulin with a spray propellant for
prandial insulin therapy. The formulation results in an aerosol with relatively large micelles
where the majority of the particles have a mean size >10 µm and therefore cannot go into the
lungs. Each puff is claimed to deliver 10 U of insulin. The absorption rate of administered
insulin as a puff is 10%, and that corresponds to 1 U when 1 puff of 10 U is delivered, which
means 10 puffs will deliver 10 U insulin for a meal.[17]
Clinical studies in healthy volunteers and subjects with type 1 and type 2 diabetes have shown
that the oral insulin spray was absorbed in direct relation to the amount given, and it had a
rapid onset and a shorter duration compared with regular insulin given subcutaneously. In
all of the studies conducted, the oral insulin spray was generally well tolerated. The only side
effects included mild episodes of transient dizziness in some healthy volunteers and subjects
with type 1 diabetes.[18] The product is on the market in a number of countries (e.g., Ecuador
and India).[17] Without appropriately designed and performed phase 3 trials at hand, it is not
possible to make any clear statement about the benefits/risk ratio of the different buccal
insulins.[17]
Oral insulin: Oral insulin has benefits in terms of compliance among patients, as well as
physiological advantages because oral insulin can mimic the physiological fate of insulin
through first pass to the liver, directly and effectively inhibiting hepatic glucose production.
[19] Since the initial discovery of insulin by Banting and Best in 1922, the oral form of insulin
has been the elusive goal. Difficulties encountered for oral insulin delivery, since it is a protein,
include degradation by the low pH of the stomach and the digestive enzymes in the stomach
and small intestine. The major barrier for insulin absorption is the intestinal epithelium. All
these factors lead to low bioavailability, and that leads to significant inter- and intra-subject
variability.
Nanotechnologies have brought some hope for improved delivery of insulin. Nanotechnology
applications for delivery of hydrophilic drugs such as insulin might be achieved using
biodegradable polymers such as chitosan, which has been extensively exploited for the
preparation of nanoparticles for oral controlled delivery of several therapeutic agents.[20-24]
In recent years, chitosan cross-linked to various hydrophobic polymers has been utilized for
the preparation of orally delivered drugs because of improved permeation and sustained
release characteristics.[25-26]
The newer products that are being tried include water-soluble, long-acting insulin derivative,
[(2-sulfo)-9-fluorenylmethoxycarbonyl]3-insulin,[27] vitamin B12-dextran nano particles,[28]
lipid nanoparticles,[29] and PEGylated calcium phosphate nanoparticles as oral carriers for
insulin.[30] Protection of insulin from the gastric environment has been achieved by coating
the nanoparticles with a pH-sensitive polymer that dissolves in the intestine at mild alkaline
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pH. In rats, oral insulin nanoformulation significantly (P<0.05) reduced blood glucose in
normal and diabetic rats.[31]
Biocon (Bangalore, India) is manufacturing IN-105, which is in late phase 3.[17] IN-105 is a
human recombinant insulin conjugated with polyethylene glycol via an acetyl chain. It is orally
bioavailable and stable at ambient conditions. Preclinical studies in different species have
shown acceptable efficacy and safety. Its maximal circulating insulin levels after oral admin‐
istration of 5 mg were observed after 20 minutes, and the maximum drop in glucose occurred
at 40 minutes after oral administration. Phase 1 and phase 2 trials demonstrated that the
absorption of IN-105 and the reduction in blood glucose levels were proportional to the dose
administered.[32]
Inhaled insulin: The inhaled products fall into two main groups: the dry powder formulations
and solution, which are delivered through different inhaler systems. Exubera®, containing
rapid-acting insulin in powder form, was studied in patients with type 1 and type 2 diabetes
mellitus.[33-34] The results of a patient preference study, using a comparison of utility scores,
showed a greater preference for the inhaled route over insulin injection.[35] However, issues
like cost, the bulkiness of the device, and the small number of studies in subjects with under‐
lying respiratory disease prevented widespread use of this new mode of delivery.[36-37]
Exubera® was available for less than one year, and then Pfizer took it off the market in 2007
because the drug failed to gain market acceptance.
Afrezza®: (MannKind Corporation, Valencia, CA, USA) is recombinant human insulin, using
the Technosphere® concept and administered using a next-generation inhaler called Dream‐
boat®. Technosphere® is a drug delivery system created by micro particles (2-3 µm) that form
microspheres, which are then lyophilized into a dry powder for inhalation.[38]
Transdermal insulin: Transdermal insulin delivery is a needle-free alternative and avoids the
disadvantages associated with other alternative routes such as the pulmonary and nasal routes.
Permeation of compounds is limited to small, lipophilic molecules. The stratum corneum, the
outermost layer of the skin, constitutes the major barrier for insulin permeation to reach useful
levels. Several chemical and physical enhancement techniques such as iontophoresis, ultra‐
sound/sonophoresis, micro-needles, electroporation, laser ablation, and chemical enhancers
have been explored to overcome the stratum corneum barrier to increase skin permeability.
Methods to improve transdermal delivery:
1. Chemical enhancers, which alter the lipid structure of the stratum.
2. Iontophoresis, which enhances the transdermal delivery of compounds via the use of a
small electric current.[39]
3. Micro-needle technology, which involves the creation of micron-sized channels in the
skin, thereby disrupting the stratum corneum barrier[40] and delivering the drug into the
epidermis without disruption of nerve endings.[41]
4. Sonophoresis, which uses ultrasound and has been shown to increase skin permeability
of insulin. It is still being evaluated.[42]
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4. Conclusions
Effective glycemic control remains an important clinical goal. Patient barriers to accepting
insulin initiation include fear of hypoglycemia, weight gain, and the inflexible timing of
scheduled insulin doses, leading to adherence issues. Additionally, the invasive nature of the
insulin syringe, pump, and pen remains an obstacle for patients. Of the alternatives to
subcutaneous and injected insulin, intranasal, inhalable, and oral insulin could prove to be the
most cost-effective ones. Oral insulin in particular could prove to be promising, especially since
as a therapy it seems to have progressed with nanotechnology research, allowing for several
types of encapsulations to bypass the gastric acidic environment. Artificial pancreas or closing
the loop with insulin pumps that deliver insulin in response to sensors also appears to be
promising.
Method Mechanism
Artificial pancreas Insulin pump controlled by algorithm with glucose monitor
Buccal insulin Insulin through an aerosol spray
Oral insulin Various nanoparticle encasings bound to insulin
Inhalable insulin Insulin absorbed through alveolar membranes
Transdermal insulin
(patches)
Insulin absorbed through pores in skin opened with ultrasound energy,
microdermabrasion, etc.
Intranasal insulin Absorbed through nasal mucosae
Table 1. Methods for Future Types of Insulin Therapy
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